Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses-Reference-Cited by-同舟云学术

Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses

Published:2019-10 Issue:3 Volume:29 Page:573-588.e7
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Botton Thomas,Talevich Eric,Mishra Vivek Kumar,Zhang Tongwu,Shain A. Hunter,Berquet Céline,Gagnon Alexander,Judson Robert L.,Ballotti Robert,Ribas Antoni,Herlyn Meenhard,Rocchi Stéphane,Brown Kevin M.,Hayward Nicholas K.,Yeh Iwei,Bastian Boris C.

Funder

NIH

Melanoma Research Alliance

The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Philippe Foundation, Inc.

Fondation ARC pour la Recherche sur le Cancer

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference73 articles.

1. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth;Bennett;Int. J. Cancer,1987

2. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy;Botton;Pigment Cell Melanoma Res.,2013

3. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis;Chakraborty;Blood,2016

4. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes;Chmielecki;Cancer Discov.,2014

5. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer;Ciampi;J. Clin. Invest.,2005

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. The mTOR pathway controls phosphorylation of BRAF at T401;Cell Communication and Signaling;2024-09-02

3. Histopathologic, genomic, transcriptomic, and functional characteristics of eight melanocytic tumors with BRAF fusions showing stronger MAPK pathway activation compared to BRAF V600E tumors;Journal of Cutaneous Pathology;2024-08-22

4. Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-08-21

5. Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine;JCO Precision Oncology;2024-07